



**NORRIS**  
**MEDICINES LIMITED**



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Regd. Office : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Telephone : (02646) 223462, 227530  
Fax : (02646) 250126  
E-mail : contact@norrispharma.com  
Website : www.norrispharma.com  
CIN : L24230GJ1990PLC086581

Date: 16<sup>th</sup> November, 2017

To,

The Manager  
Listing Department  
The Bombay Stock Exchange Ltd,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

**Scrip Code: 524414**

**Sub: Submission of Standalone Unaudited Financial Results in Compliance with Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

1. Standalone Unaudited Financial Results of the Company for the quarter and Six months ended 30<sup>th</sup> September, 2017.
2. Limited Review Report by Statutory Auditors on Unaudited Financial Results for the quarter and Six months ended 30<sup>th</sup> September, 2017

Thanking you,

Yours faithfully,  
For **NORRIS MEDICIENS LIMITED**

  
**Vinay Rana**  
(Company Secretary)



**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2017**  
(Rs. In Lacs)

| Sr. No.  | Particulars  | Quarter Ended  |               |               | Six Months Ended |                | Previous Year Ended |
|----------|--|----------------|---------------|---------------|------------------|----------------|---------------------|
|          |  | 30.09.2017     | 30.06.2017    | 30.09.2016    | 30.09.2017       | 30.09.2016     | 31.03.2017          |
|          |  | Unaudited      | Rewiewed      | Unaudited     | Rewiewed         | Unaudited      | Audited             |
| <b>1</b> | <b>Income from operation</b>   |                |               |               |                  |                |                     |
|          | Revenue from Operations  | 323.63         | 350.86        | 664.17        | 674.49           | 1082.06        | 2045.68             |
|          | Other Income   | 0.82           | 0.57          | 0.18          | 1.39             | 0.25           | 13.96               |
|          | <b>Total Income</b>  | <b>324.45</b>  | <b>351.43</b> | <b>664.35</b> | <b>675.88</b>    | <b>1082.31</b> | <b>2059.64</b>      |
| <b>2</b> | <b>Expenses</b>  |                |               |               |                  |                |                     |
|          | (a) Cost of materials consumed   | 183.21         | 122.94        | 349.69        | 306.15           | 541.98         | 1052.05             |
|          | (b) Change in inventories of finished goods work in progress and stock-in-trade  | 19.04          | 46.23         | 35.57         | 65.27            | 43.24          | -11.97              |
|          | (c) Employee benefits expense  | 119.26         | 138.11        | 139.74        | 257.37           | 256.23         | 530.78              |
|          | (d) Finance cost   | 19.33          | 17.33         | 12.73         | 36.66            | 24.88          | 60.12               |
|          | (e) Depreciation and amortisation expense  | 16.15          | 16.15         | 14.50         | 32.30            | 29.00          | 64.60               |
|          | (f) Other Expense  | 85.01          | 101.41        | 116.70        | 186.42           | 214.18         | 482.36              |
|          | <b>Total Expenses</b>  | <b>442.00</b>  | <b>442.17</b> | <b>668.93</b> | <b>884.17</b>    | <b>1109.51</b> | <b>2177.94</b>      |
| <b>3</b> | <b>Profit / (Loss) before Tax</b>  | <b>-117.55</b> | <b>-90.74</b> | <b>-4.58</b>  | <b>-208.29</b>   | <b>-27.20</b>  | <b>-118.30</b>      |
| <b>4</b> | <b>Tax Expense</b>   |                |               |               |                  |                |                     |
|          | (a) Current Tax  | 0.00           | 0.00          | 0.00          | 0.00             | 0.00           | 0.00                |
|          | (b) Deferred Tax   | 0.00           | 0.00          | 0.00          | 0.00             | 0.00           | 41.57               |
| <b>5</b> | <b>Profit / (Loss) after tax for the period</b>                                  | <b>-117.55</b> | <b>-90.74</b> | <b>-4.58</b>  | <b>-208.29</b>   | <b>-27.20</b>  | <b>-76.73</b>       |
| <b>6</b> | <b>Other Comprehensive Income</b>  |                |               |               |                  |                |                     |
| (a)      | (i) Item that will not be reclassified to profit or loss                         | 0.00           | 0.00          | 0.00          | 0.00             | 0.00           | 0.00                |
|          | (ii) Income Tax relating to item that will not be reclassified to profit or loss | 0.00           | 0.00          | 0.00          | 0.00             | 0.00           | 0.00                |
| (b)      | (i) Item that will be reclassified to profit or loss                             | 0.00           | 0.00          | 0.00          | 0.00             | 0.00           | 0.00                |
|          | (ii) Income Tax relating to item that will be reclassified to profit or loss     | 0.00           | 0.00          | 0.00          | 0.00             | 0.00           | 0.00                |
| <b>7</b> | <b>Total Comprehensive Income for the period</b>                                 | <b>-117.55</b> | <b>-90.74</b> | <b>-4.58</b>  | <b>-208.29</b>   | <b>-27.20</b>  | <b>-76.73</b>       |
|          | <b>Basic and Diluted Earning per equity share</b>                                | <b>-1.18</b>   | <b>-0.91</b>  | <b>-0.05</b>  | <b>-2.08</b>     | <b>-0.95</b>   | <b>-0.77</b>        |

**Notes:**

- The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 16/11/2017.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- The above Results, have been prepared in accordance with Ind AS notified under the companies (Indian Accounting Standards) Rules, 2015.

Reconciliation of Net Profit between Previous GAAP and Ind AS:

**Standalone Financial Results.**

| Nature of Adjustment  | Rs. In Lacs              |                             |
|---|--------------------------|-----------------------------|
|   | Quarter Ended 30.09.2016 | Six Months Ended 30.09.2016 |
| Net Profit Under Previous GAAP  | -4.58                    | -27.2                       |
| Actuarial gain / (Loss) on employees defined benefit funds recognised in Other Comprehensive Income (Net) | -                        | -                           |
| Net gain / (Loss) on financial assets at fair value through profit and Loss                               | -                        | -                           |
| Net Profit under per Ind As   | -4.58                    | -27.2                       |

- Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures.

For NORRIS MEDICINES LIMITED



Vimal D Shah  
Managing Director

Date : 16th November, 2017  
Place : Ankleshwar

| STATEMENT OF ASSETS AND LIABILITIES           | 30.09.2017      | 31.03.2017      |
|---|-----------------|-----------------|
|   | (Unaudited)     | (Audited)       |
| <b>I. EQUITY AND LIABILITIES</b>              |                 |                 |
| <b>(1) Shareholder's Funds</b>                |                 |                 |
| (a) Share Capital                             | 992.57          | 992.57          |
| (b) Reserves & Surplus                        | -744.73         | -536.42         |
| <b>Sub Total- Shareholder's Fund</b>          | <b>247.84</b>   | <b>456.15</b>   |
| (2) Share Application money pending allotment | -               | -               |
| (3) Minority Interest                         | -               | -               |
| <b>(4) Non - Current Liabilities</b>          |                 |                 |
| (a) Long Term borrowings                      | 768.93          | 757.00          |
| (b) Deferred Tax Liabilities(Net)             | -               | -               |
| (c) Othr Long term Liabilities                | -               | -               |
| (d) Long Term provisions                      | -               | -               |
| <b>Sub Total- Non-Current Liabilities</b>     | <b>768.93</b>   | <b>757.00</b>   |
| <b>(5) Current Liabilities</b>                |                 |                 |
| (a) Short Term borrowings                     | 267.35          | 370.72          |
| (b) Trade payables                            | 280.84          | 356.99          |
| (c) Other current liabilities                 | -               | 196.37          |
| (d) Short Term provisions                     | 94.74           | 67.15           |
| <b>Sub Total-Current Liabilities</b>          | <b>642.93</b>   | <b>991.23</b>   |
|   |                 |                 |
| <b>TOTAL EQUITY AND LIABILITIES</b>           | <b>1,659.70</b> | <b>2,204.38</b> |
| <b>II. ASSETS</b>                             |                 |                 |
| <b>(1) Non -current assets</b>                |                 |                 |
| (a) Fixed Assets                              |                 |                 |
| (i) Tangible assets                           | 966.40          | 997.14          |
| (ii) Intangible Assets                        | -               | -               |
| (iii) Capital Work in Progress                | -               | -               |
| (iv) Intangible Assets under Development      | -               | -               |
| (b) Non Current investments                   | 29.05           | 0.88            |
| (c) Deferred tax assets (net)                 | 181.09          | 181.09          |
| (d) Long Term Loans and Advances              | 27.94           | 119.57          |
| <b>Sub Total- Non-Current Assets</b>          | <b>1204.48</b>  | <b>1298.68</b>  |
| <b>(2) Current Assets</b>                     |                 |                 |
| (a) Current investments                       | -               | -               |
| (b) Inventories                               | 222.84          | 368.90          |
| (c) Trade Receivables                         | 170.59          | 472.47          |
| (d) Cash & cash equivalents                   | 12.38           | 4.65            |
| (e) Short Term Loans and advances             | 47.36           | 59.68           |
| (f) Other Current assets                      | 2.05            | -               |
| <b>Sub Total- Non-Current Assets</b>          | <b>455.22</b>   | <b>905.70</b>   |
|   |                 |                 |
| <b>TOTAL ASSETS</b>                           | <b>1,659.70</b> | <b>2,204.38</b> |

Date : 16th November, 2017

Place : Ankleshwar, Gujarat.





C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.  
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

Date : 16<sup>th</sup> November, 2017

To  
The Board of Directors  
Norris Medicines Limited  
Ankleshwar.

**Limited Review Report on Standalone Quarterly Financial Results of Norris Medicines Limited to the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015**

1. **INTRODUCTION**

We have reviewed the accompanying statement of Standalone unaudited financial results of **Norris Medicines Limited** ("the company") for the period ended on **30<sup>th</sup> September, 2017** which is Ind AS compliant.

Attention is invited to the fact that the figures for the corresponding quarter/ half year ended on 30<sup>th</sup> September, 2016 and year ended on 31<sup>st</sup> March, 2017 including the reconciliation of net profits between Ind AS and previous Indian GAAP for the quarter/ half year ended on 30<sup>th</sup> September, 2016, are Ind AS compliant. These are not required to be subjected to limited to limited review, as permitted by SEBI circular CIR/CFD/FAC/62/2016 dated July 05, 2016.

Management is responsible for the preparation and fair presentation of this standalone interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to express a conclusion on this standalone interim financial information based on our review. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.

2. **SCOPE OF REVIEW**

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, **Review of Interim Financial Information Performed by the Independent Auditor of the Entity** issued by the Institute of Chartered Accountants of India.





C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.  
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. **SCOPE OF REVIEW**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Thanking You,

Yours Faithfully

For, H. N. JADAV & Co.  
Chartered Accountants  
Firm Reg. No.: 103801W



CA. Harishchandra N. Jadav  
(Proprietor)  
M. No. 040525